LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Firestein & Kelley’s Textbook of Rheumatology, 2-Volume Set
- 12th Edition - July 24, 2024
- Editors: Gary S. Firestein, Iain B McInnes, Gary Koretzky, Ted Mikuls, Tuhina Neogi, James R. O'Dell
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 3 5 4 0 - 1
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 3 5 0 5 1 - 1
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 3 5 9 0 - 6
With its comprehensive, global coverage of all aspects of diagnosis, screening, and treatment in both adults and children, Firestein & Kelley’s Textbook of Rheumatology re… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteWith its comprehensive, global coverage of all aspects of diagnosis, screening, and treatment in both adults and children, Firestein & Kelley’s Textbook of Rheumatology remains your reference of choice in this evolving field. The fully revised 12th Edition retains the user-friendly, full color format, providing in-depth guidance in rheumatology with an ideal balance of basic science and clinical application. New editors, new chapters, and new illustrations keep you fully up to date on recent advances in genetics and the microbiome, current therapies, and other rapid changes in the field.
- Covers everything from basic science, immunology, anatomy, and physiology to diagnostic tests, procedures, physical examination, and disease pathogenesis, manifestations and treatment―including key data on outcomes to better inform clinical decision making.
- Includes new or significantly revised chapters on Pre-Clinical Autoimmunity; The Microbiome in Health and Disease; Physical Therapy and Rehabilitation; Nutrition and Rheumatic Disease; Classification and Epidemiology of Spondyloarthritis; Etiology and Pathogenesis of Osteoarthritis; COVID and Rheumatic Disease; Vaccination in Rheumatic Disease; Autoimmune Complications of Immune Checkpoint Inhibitors for Cancer; and many more.
- Features 1,200 high-quality illustrations, including superb line art, quick-reference tables, and full-color clinical photographs; many new illustrations highlight diseases among racially diverse patients.
- Shares the knowledge and expertise of internationally renowned scientists and clinicians, including new editors Drs. Ted Mikuls and Tuhina Neogi.
- Demonstrates the complete musculoskeletal exam in online videos, including abnormal findings and the arthroscopic presentation of diseased joints.
- An eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud. Additional digital ancillary content may publish up to 6 weeks following the publication date.
- Instructions for online access
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- Preface
- Volume I
- Part 1. Structure and Function of Bone, Joints, and Connective Tissue
- 1. Developmental Biology, Organization, and Function of the Synovial Joints
- Classification of Joints
- Developmental Biology of Limb Diarthrodial Joints and Skeletal Elements
- Organization and Physiology of the Mature Joint
- Conclusion
- 2. Synovium
- Structure
- Function
- Conclusion
- 3. Cartilage and Chondrocytes
- Introduction
- Cartilage Structure
- Structure–Function Relationships of Cartilage Matrix Components
- Morphology, Classification, and Normal Function of Chondrocytes
- Interactions of Chondrocytes With the Extra-cellular Matrix
- Angiogenic and Antiangiogenic Factors
- Roles of Growth and Differentiation (Anabolic) Factors in Normal Cartilage Metabolism
- Epigenetic Regulation of Cartilage Homeostasis
- Role of the Chondrocyte in Cartilage Pathology
- Conclusion
- 4. Development and Biology of Bone
- Structure and Composition of Bone
- Bone Remodeling
- Conclusion
- 5. Muscle Anatomy, Physiology, and Biochemistry
- Introduction
- Structure
- Muscle Architecture
- Physiology
- Energy and Biochemistry
- Plasticity
- Conclusion
- 6. Biomechanics
- Introduction
- Kinematics
- Kinetics
- Joint Mechanics
- Joint Constraint and Stability
- Mechanical Loading on Tendon
- Mechanical Loading on Bursae
- Conclusion
- 7. Regenerative Medicine and Tissue Engineering
- Introduction
- Extrinsic Repair: Current Therapeutic Interventions
- Cell Therapy for Osteoarthritis
- Intrinsic Repair
- Conclusion
- 8. Proteinases and Matrix Degradation
- Introduction
- Extra-cellular Matrix–Degrading Proteinases
- Regulation of Proteinase Activity
- Joint Tissue Destruction in Arthritis
- Conclusion
- Part 2. Cells Involved in Autoimmune Diseases and Inflammation
- 9. Dendritic Cells
- Introduction
- Dendritic Cell Subsets and Development
- Dendritic Cell Maturation and Activation
- Antigen Processing and Presentation
- Impairment of Dendritic Cell Biology in Diseases
- Immunotherapeutic Strategies and Clinical Trials
- Conclusion
- 10. Mononuclear Phagocytes
- Introduction
- Macrophage Origin: Nature Versus Nurture
- Mononuclear Phagocytes in Rheumatoid Arthritis
- Human Macrophage Heterogeneity: Where Do We Go From Here?
- 11. Neutrophils
- Introduction
- Neutrophils: Basic Principles
- Neutrophil Functions
- Heterogeneity
- Role of Neutrophils, Low-Density Granulocytes, and Neutrophil Extra-cellular Traps in Rheumatic Diseases
- Targeting Neutrophils and Neutrophil Extra-cellular Traps in Systemic Autoimmune Diseases
- Conclusion
- 12. T Lymphocytes
- Introduction
- T Cell Development
- Immunodeficiencies Resulting From Defects in T Cell Development
- Peripheral Migration and Homeostatic Proliferation of T Cells
- Activation of T Cells
- Tolerance and Control of Autoreactive T Cells
- T Cell Subsets
- Inflammation Mediated by T Cells
- Termination of T Cell Responses
- Conclusion
- 13. B Cells
- Introduction
- Immunoglobulins: Structure and Function
- Glycosylation
- B Cell Development
- B Cell Activation and Differentiation
- Repertoire Selection
- Molecular Triggers of Autoimmunity
- Conclusion
- 14. Fibroblasts andFibroblast-like Synoviocytes
- Introduction
- What Is a Fibroblast?
- Physiologic Characteristics and Functions of Fibroblasts
- Role of Fibroblasts in Persistent Inflammation
- Fibroblast-like Synoviocytes in Rheumatoid Arthritis
- Lessons Learned From Cancer
- Conclusion
- 15. Mast Cells and Basophils
- Introduction
- Mast Cells and Basophils in Ancient Innate Immunity
- Distinguishing Features of Mast Cells and Basophils
- IgE-Dependent Upregulation of FcεRI Expression and FcεRI-Dependent Function
- Mast Cell and Basophil Heterogeneity
- Genetic Approaches for Analyzing Mast Cell and Basophil Function
- Immunoregulatory Functions of Mast Cells and Basophils
- Biological Functions of Mast Cells and Basophils
- Conclusion
- 16. Innate Lymphoid Cells and Natural Killer Cells
- Introduction
- Distinguishing Human ILCs and NK Cells
- Target Recognition by NK Cells and Killer Immunoglobulin-like Receptors
- Biology of ILCs and NK Cells
- Role of NK Cells in Rheumatic Disease
- Role of ILCs in Rheumatic Disease
- Conclusion
- 17. Platelets and Megakaryocytes
- Introduction
- Platelet Structure
- Platelet Production
- Platelets and Hemostasis
- Signaling Pathways in Platelet Activation
- The Platelet as an Immune Cell
- The Megakaryocyte as an Immune Cell
- Platelets, Megakaryocytes, and Rheumatic Diseases
- Conclusion
- Part 3. Effector Mechanisms in Autoimmunity and Inflammation
- 18. Principles of Signaling
- Introduction
- Receptors With Enzymatic Activity
- Receptors That Recruit Molecules With Enzymatic Activity
- Sphingosine 1-Phosphate
- Innate Receptor Signaling
- Intra-cellular Receptor Signaling
- Adaptor Molecules
- Signaling Pathways
- Transcription Factors
- Conclusion
- 19. Innate Immunity
- Introduction
- Evolutionary Origins of Innate Immunity
- Pathogen Recognition by the Innate Immune System
- PAMPs and DAMPs: Patterns for Innate Immune Recognition
- Effector Mechanisms of Innate Immune Responses
- Influence of Innate Mechanisms on Adaptive Immunity
- Disease Associations Involving Innate Immunity
- Conclusions
- 20. Adaptive Immunity
- Introduction
- Phylogenetic Appearance of the Adaptive Immune System
- Cardinal Features of the Adaptive Immune System
- Cells of the Adaptive Immune System
- Development of Adaptive Immune Cells
- Anatomic Organization of the Peripheral Adaptive Immune System
- Trafficking of Adaptive Immune Cells
- Cell-to-Cell Interactions That Support Development of an Immune Response
- Consequences of Failed Development or Activation of the Adaptive Immune System
- Conclusion
- 21. Immune Tolerance and Autoimmunity
- Introduction
- Definition and Classification of Pathogenic Autoimmunity
- Animal Models of Autoimmunity
- Tolerance Mechanisms
- Theories of Autoimmunity
- Immunological Mechanisms of Tissue Inflammation and Dysfunction
- Pathophysiology of Autoimmune Rheumatic Diseases
- Genetics of Autoimmune Diseases
- Sex and Autoimmunity
- Microbial and Other Environmental Triggers
- Conclusion
- 22. Pre-clinical Autoimmunity
- Introduction
- Defining Pre-classification Autoimmunity: More Than Just Semantics
- Population Epidemiology of Autoimmunity
- Type 1 Diabetes as a Paradigm for Pre-classification Autoimmunity
- Pre-classification Systemic Autoimmune Disease
- Conclusion
- 23. The Microbiome in Rheumatic Diseases
- Introduction
- Microbiome Analyses
- The Microbiota in Rheumatic Diseases
- Microbiota Therapies
- Conclusion
- 24. Genetics of Rheumatic Diseases
- Introduction
- Evidence for a Genetic Component to Rheumatic Diseases
- Study Design
- Susceptibility Genes in Rheumatic Disease
- Clinical Translation
- Identification of High-Risk Groups
- 25. Epigenetics of Rheumatic Diseases
- Introduction
- Epigenetic Regulation
- Epigenetics and the Immune Response
- Challenges Faced in Translational Epigenetics Research
- Epigenetics in Rheumatic Diseases
- Integration of Epigenetic Data Streams and Clinical Applications
- Conclusion
- 26. Complement System
- Introduction
- Functions of the Complement System
- Terminology to Describe Complement and Its Activation Fragments
- Activation Pathways
- Regulation of Complement Activation
- Receptors for Complement Fragments
- Functions of the Complement System
- Complement Deficiency
- Targeted Complement Therapeutics
- Complement in Rheumatic Diseases
- Conclusion
- 27. Prostaglandins, Leukotrienes, and Related Compounds
- Introduction
- Biosynthesis of Eicosanoids
- Products of the Cyclooxygenase Pathway
- Eicosanoid Receptors
- Platelet-Activating Factor
- Eicosanoids as Regulators of Inflammation and Immune Responses
- Modulation of Eicosanoid Synthesis by Administration of Precursor Fatty Acids
- 28. Angiogenesis
- Introduction
- Endothelial Cells
- Angiogenesis
- Regulators of Angiogenesis
- Hypoxia, Cell Metabolism, and Angiogenesis
- Angiogenic Mechanisms in Rheumatoid Arthritis and Spondyloarthropathies
- Targeting Angiogenesis
- Conclusion
- 29. Cytokines and Chemokines
- Introduction
- Cytokine Receptors
- Regulation of Cytokine Expression
- Effector Function of Cytokines
- Chemokines
- Conclusion
- 30. Neuronal Mechanisms of Pain and Inflammation
- Introduction
- Peripheral Pain Pathways
- Pain-Resolving Pathways in the Periphery
- Interactions Between Peripheral Pain Pathways and the CNS
- Systemic Factors Contributing to Pain Heterogeneity in Rheumatic Diseases
- Efferent Actions of Nociceptive Pathways
- Clinical Scenarios
- Conclusions
- Part 4. Broad Issues in the Approach to Rheumatic Disease
- 31. Clinical Research Methods in the Rheumatic Diseases
- Data Sources for Research in Rheumatology
- Measures of Occurrence
- Measures of Association
- Study Designs
- Clinical Trial Considerations
- Common Sources of Bias
- Effect Measure Modification, Interaction, and Heterogeneity
- Surveillance and Screening
- Conclusion
- 32. Epidemiology and Impact of Rheumatic Diseases
- Epidemiology of Arthritis and Other Rheumatic Diseases
- Arthritis-Attributable Costs
- Public Health Approaches to Arthritis Self-Management
- Conclusion
- 33. Assessment of Health Outcomes
- Introduction
- Types of Outcomes
- Evaluation and Endorsement of Outcomes
- Review of Disease-Specific Outcomes
- Measures That Address Symptoms and Individual Health Domains
- Imaging and Biomarker Outcomes
- Health Outcomes in Real-World Settings
- Conclusion
- 34. Biomarkers in Rheumatology
- Biomarker Definitions and Applications
- Defining Patient Heterogeneity
- Pitfalls in Translation From Biomarker Discovery to Clinical Utility
- Surrogate Biomarkers
- Companion Diagnostics Versus CLIA Regulatory Routes
- Safety Biomarkers
- Biomarkers in Rheumatic Diseases
- Biomarkers in Osteoarthritis
- Biomarkers in Rheumatoid Arthritis
- Biomarkers in Systemic Lupus Erythematosus
- Next Horizons for Biomarkers
- 35. Occupational, Environmental, and Recreational Musculoskeletal Disorders
- Introduction
- Occupation-Related Musculoskeletal Disorders
- Occupation-Related Rheumatic Diseases
- Recreation- and Sports-Related Musculoskeletal Disorders
- Performing Arts–Related Musculoskeletal Disorders
- 36. Cardiovascular Risk in Inflammatory Rheumatic Disease
- Introduction
- Biologic Mechanisms: Relationship Between Inflammation and Cardiovascular Disease
- Cardiovascular Morbidity and Mortality in Rheumatoid Arthritis and Systemic Lupus Erythematosus
- Risk Factors for Cardiovascular Disease
- Cardiovascular Mortality, Morbidity, and Risk Factors in Other Rheumatic Diseases
- Managing Cardiovascular Risk in Rheumatic Disease
- Cardiovascular Disease Risk Assessment
- Conclusion
- 37. Cancer Risk in Rheumatic Diseases
- Introduction
- Malignancy in Autoimmune Rheumatic Diseases
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Systemic Sclerosis (Scleroderma)
- Idiopathic Inflammatory Myopathy
- Sjögren’s Syndrome
- Vasculitis
- Seronegative Spondyloarthritis
- Cancer Risks Associated With Anti-rheumatic Drug Therapies
- Conventional (Traditional) Nonbiologic DMARD Therapy
- Biologic Response Modifiers
- Immune Checkpoint Inhibitors
- Cancer Screening in Patients With Rheumatic Disease
- Conclusion
- 38. Occupational Therapy, Physical Therapy, and Rehabilitation
- Introduction
- Role of Rehabilitation in Rheumatology
- Components of Rehabilitation
- Incorporating PT/OT Into Rheumatology Practice
- Conclusion
- 39. General Principles of Pregnancy and Rheumatic Disease: Pre-pregnancy Assessment
- Introduction
- Interplay of Rheumatic Disease and Pregnancy Physiology
- General Principles of Pregnancy and Rheumatic Disease: Pre-pregnancy Assessment
- Systemic Lupus Erythematosus
- Overlap Syndromes and Undifferentiated Connective Tissue Disease
- Sjögren’s Syndrome
- Antiphospholipid Syndrome
- Inflammatory Arthritis
- Inflammatory Myositis
- Systemic Sclerosis
- Vasculitis
- Medications During Pregnancy and Breastfeeding
- Paternal Medication Use
- Pregnancy-Related Issues for Rheumatic Disease Patients
- Conclusion
- Part 5. Evaluation of Generalized and Localized Symptoms
- 40. History and Physical Examination of the Musculoskeletal System
- History in a Patient With Musculoskeletal Disease
- Systematic Method of Physical Examination
- Recording the Joint Examination
- Interpreting the Joint Examination
- Examination of Specific Joints
- 41. Ultrasound in Rheumatology
- Introduction
- Technical Aspects
- Artifacts
- Examination Technique
- Ultrasound in Rheumatology Definitions
- Rheumatoid Arthritis
- Osteoarthritis
- Crystalline Arthropathy
- Spondyloarthritis
- Polymyalgia Rheumatica
- Giant Cell Arteritis
- Sjögren’s Syndrome
- Fibrotic Diseases
- Non-inflammatory Conditions
- Pediatric Rheumatology
- Ultrasound in Rheumatology Intervention
- Conclusion
- 42. Evaluation of Monoarticular and Polyarticular Arthritis
- Introduction
- Approach to the Patient With Arthritis
- Differential Diagnosis
- Formal Criteria and Their Role in Clinical Diagnosis
- Preliminary Diagnoses, Working Diagnoses, Presumptive Treatments, Reassessments, and Future Perspectives
- 43. Skin and Rheumatic Diseases
- Introduction
- Psoriasis
- Reactive Arthritis
- Rheumatoid Arthritis
- Juvenile Rheumatoid Arthritis and Still’s Disease
- Lupus Erythematosus
- Neonatal Lupus Syndrome
- Sjögren’s Syndrome
- Dermatomyositis
- Morphea, Systemic Sclerosis, and Other Sclerosing Conditions
- Primary Vasculitis Involving the Skin
- Infections
- Panniculitis
- Relapsing Polychondritis
- Infiltrative Diseases
- Miscellaneous Skin Diseases and Arthritis
- 44. The Eye and Rheumatic Diseases
- Introduction
- Ocular Anatomy and Physiology
- Ocular Immune Response
- Uveitis
- Scleritis and Corneal Melt
- Orbital Disease
- Optic Neuritis
- Medication-Related Ocular Toxicity
- Conclusion
- Part 6. Differential Diagnosis of Regional and Diffuse Musculoskeletal Pain
- 45. Neck Pain
- Epidemiology
- Anatomy
- Axial Neck Pain
- Radiculopathy and Myelopathy
- Infection and Neoplasm
- Clinical Features
- Diagnostic Evaluation
- Differential Diagnosis and Treatment
- 46. Shoulder Pain
- Introduction
- Anatomy and Function
- Diagnosis
- Intrinsic Factors Causing Shoulder Pain
- Extrinsic or Regional Factors Causing Shoulder Pain
- 47. Low Back Pain
- Introduction and Epidemiology
- Anatomy
- Clinical Evaluation
- Differential Diagnosis
- Treatment
- Outcome
- Conclusion
- 48. Hip and Knee Pain
- Introduction
- Knee Pain
- Hip Pain
- 49. Foot and Ankle Pain
- Introduction
- Functional Anatomy and Biomechanics
- Diagnostic Evaluation
- Imaging
- Differential Diagnosis of Ankle Pain
- Differential Diagnosis of Foot Pain
- Nonsurgical Treatment
- Surgical Treatment
- Conclusion
- 50. Hand and Wrist Pain
- Introduction
- Patient Evaluation
- Physical Examination
- Common Causes of Hand and Wrist Pain
- 51. Temporomandibular Joint Disorders
- Introduction
- Congenital and Acquired Temporomandibular Joint Disorders
- Temporomandibular Joint Diseases
- Arthralgia
- Masticatory Muscle Pain
- Neuroplasticity, Nociplasticity, and Chronic Pain
- TMD Management Strategies
- Conclusion
- 52. Fibromyalgia
- Introduction
- Historical Perspective
- Diagnostic Criteria
- Epidemiology
- Clinical Features
- Differential Diagnosis and Comorbidities
- Assessment of Severity
- Mechanisms of Disease
- Social and Psychological Factors
- Treatment Approaches
- Outcome
- Part 7. Diagnostic Tests and Procedures in Rheumatic Diseases
- 53. Synovial Fluid Analyses, Synovial Biopsy, and Synovial Pathology
- Introduction
- Synovial Fluid Analysis
- Biochemical Analysis of Synovial Fluid
- Synovial Biopsy
- Synovial Pathology
- Synovial Immunohistology
- Conclusion
- 54. Arthrocentesis and Injection of Joints and Soft Tissues
- Introduction
- Indications, Contraindications, and Potential Complications of Arthrocentesis and Soft Tissue Injections
- Drugs and Preparations Used for Injection
- Procedures Description
- Upper Limb Injections
- Lower Limb Injections
- Soft Tissue Injections: Upper Limbs
- Soft Tissue Injections: Lower Limbs
- Conclusion
- 55. Anti-nuclear Antibodies
- Introduction
- Methods of Detection
- Relevance of Anti-nuclear Antibodies to Disease Pathogenesis
- Diseases Primarily Associated With Anti-nuclear Antibodies
- Specific ANA Clinical Scenarios
- Recommendations for Anti-nuclear Antibody Testing
- 56. Autoantibodies in Rheumatoid Arthritis
- Introduction
- Citrullination-Associated Autoantibodies
- Antibodies to Post-translational Modifications With Structural Similarity to Citrulline
- Antibodies to Malondialdehyde-Acetaldehyde Adducts
- Implications of the Anti-modified Protein Antibodies Concept
- Other RA Autoantibodies
- Conclusion
- 57. Acute Phase Reactants
- Introduction
- Acute Phase Response
- Acute Phase Reactants in the Management of Rheumatic Diseases
- Practical Use of Acute Phase Reactants
- C-Reactive Protein and Health: Associations With Nonrheumatologic Conditions
- 58. Imaging in Rheumatic Diseases
- Introduction
- Radiography
- Computed Tomography
- Magnetic Resonance Imaging
- Conclusion
- Volume II
- Part 8. Pharmacology of Anti-rheumatic Drugs
- 59. Therapeutic Targeting of Prostanoids
- Introduction
- History
- Mechanism of Action
- Pharmacology and Dosing
- Therapeutic Effects
- Adverse Effects
- Effects of Concomitant Drugs, Diseases, and Aging
- Choosing Anti-inflammatory Analgesic Therapy
- Conclusion
- 60. Glucocorticoid Therapy
- Introduction
- Structure and Classification of Steroid Hormones
- Release of Endogenous Glucocorticoids
- Glucocorticoid Mechanisms of Action
- Pharmacology of Glucocorticoids
- Glucocorticoid Use in the Treatment of Autoimmune Rheumatic Diseases
- Adverse Effects of Glucocorticoids
- Glucocorticoid Use in Pregnancy and Lactation
- Adrenal Insufficiency
- “Stress-Dose” Glucocorticoids
- Conclusion
- 61. Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies
- Methotrexate
- Leflunomide
- Sulfasalazine
- Anti-malarials
- Combination DMARD Therapy in Rheumatoid Arthritis
- 62. Immunosuppressive Drugs
- Introduction
- Cyclophosphamide
- Azathioprine
- Mycophenolate Mofetil
- Cyclosporine, Voclosporin, and Tacrolimus
- Conclusion
- 63. Anti-cytokine Biologics
- Introduction
- Tumor Necrosis Factor
- Interleukin-1
- Interleukin-6
- Interleukin-17
- Interleukin-12/23
- Novel Cytokine Inhibition
- Biosimilars
- JAK–STAT Pathway
- Monitoring
- Pregnancy and Breastfeeding
- Vaccinations
- Conclusion
- 64. Cell-Targeted Biologics and Emerging Targets: Rituximab, Abatacept, and Other Biologics
- Introduction
- Targeting B Cells
- Checkpoint Modulation
- Conclusion
- 65. Janus Kinase and Other Intra-cellular Targets
- Introduction
- Signal Transduction Pathways
- Janus Kinase Inhibitors
- JAK Inhibitors for Other Rheumatic Diseases
- Conclusion
- 66. Urate-Lowering Therapy
- Introduction
- Nonpharmacologic Treatment in Hyperuricemia
- Xanthine Oxidase Inhibition
- Febuxostat
- Uricosurics
- Uricases
- Urate-Lowering Drugs in Development
- 67. Bisphosphonates
- Introduction
- Clinical Pharmacology
- Chemistry of Bisphosphonates
- Pharmacokinetics
- Molecular Mechanism of Action
- Treatment Effects and Indications
- Adverse Effects and Tolerability
- 68. Analgesic Agents in Rheumatic Disease
- Introduction
- Physiology of Pain Perception (the Pain Experience)
- Pain Classification
- Pharmacologic Treatment of Chronic Pain
- Opioids
- Anti-depresssants
- Anti-convulsants
- Muscle Relaxants
- Emerging Targets
- 69. Nutrition and Rheumatic Diseases
- Introduction
- Challenges in Studying Dietary Effects
- Weight Loss
- What Do We Know About Exclusion Diet in Inflammatory Arthritis?
- What Do We Know About Mediterranean Dietary Pattern and Omega-3 Fatty Acids?
- Specific Dietary Supplements
- How to Deal With Diet in Patients With Inflammatory Arthritis: Practical Aspects
- Diet and Other Types of Arthritis
- Conclusion
- Part 9. Rheumatoid Arthritis and Sjögren’s Syndrome
- 70. Etiology of Rheumatoid Arthritis
- Introduction
- How Rheumatoid Arthritis Begins
- Genetic and Environmental Risk
- Autoimmunity and Innate Immunity
- Infectious Agents and the Microbiome
- Microbiome
- Changing Epidemiology
- 71. Pathogenesis of Rheumatoid Arthritis
- Introduction
- Synovial Features, Cell Types, and Biology
- Synovial Fluid and the Synovial Fluid Cartilage Interface
- Peripheral Blood Lymphocytes
- Role of T Cell Cytokines
- Macrophage and Fibroblast Cytokines
- Signal Transduction and Transcription Factors
- Cell Survival and Death in Rheumatoid Synovium
- Synovial Vasculature
- Cartilage and Bone Destruction
- Conclusion
- 72. Clinical Features of Rheumatoid Arthritis
- Epidemiology and Disease Burden
- Pre-rheumatoid Arthritis
- Clinical Presentations of Early Rheumatoid Arthritis
- Course and Complications of Established Rheumatoid Arthritis
- 73. Treatment of Rheumatoid Arthritis
- Introduction
- Goal of Rheumatoid Arthritis Treatment
- Classes of Medications
- Treatment Approaches and Strategies
- Managing Patients “At Target” Who Are Taking Disease-Modifying Anti-rheumatic Drugs
- Prevention Trials: A Step in the Right Direction
- Interpreting Radiographic Progression and the Use of Other Imaging Modalities
- Adjuncts to Medications
- Comorbidities and the Interactions of Rheumatologists With Primary Care Physicians
- Perioperative Management of Rheumatoid Arthritis Medications
- Patients With Rheumatoid Arthritis Are Doing Better
- Conclusion
- 74. Sjögren’s Syndrome
- Historical Perspective
- Definitions and Classification Criteria
- Epidemiology
- Etiology and Pathogenesis
- Clinical Features
- Diagnosis and Diagnostic Tests
- Treatment
- Outcome
- Conclusion
- Part 10. Spondyloarthritis
- 75. Classification and Epidemiology of Spondyloarthritis
- Introduction
- Classification Criteria
- Epidemiology of Spondyloarthritis
- 76. Axial Spondyloarthritis
- Introduction
- Classification Criteria for Ankylosing Spondylitis and Axial Spondyloarthritis
- Epidemiology
- Genetics and Pathogenesis
- Clinical Manifestations
- Imaging
- Diagnosis
- Prognosis and Outcomes
- Monitoring and Management
- Conclusion
- 77. Reactive Arthritis
- Introduction and Historical Background
- Epidemiology
- Etiology and Triggering Organisms
- Clinical Features
- Laboratory, Radiographic, and Advanced Imaging Findings
- Diagnosis
- Treatment
- Conclusion
- 78. Psoriatic Arthritis
- Introduction
- Epidemiology
- Clinical Features
- Differential Diagnosis
- Laboratory Features
- Radiographic Features
- Diagnosis and Classification Criteria
- Clinical Course and Outcome
- Comorbidities in Psoriatic Arthritis
- Outcome Domains and Instruments
- Pathogenesis
- Treatment
- Conclusion and Future Research Agenda
- 79. Inflammatory Bowel Disease–Associated Arthritis and Other Enteropathic Arthropathies
- Introduction
- Inflammatory Bowel Disease–Associated Arthritis
- Pathophysiology of Spondyloarthritis and Inflammatory Bowel Disease: From Gut Mucosa and Microbiome to Joint Disease
- Clinical Manifestations and Diagnosis of Inflammatory Bowel Disease–Associated Arthritis
- Assessment and Monitoring of Disease Activity
- Management
- Other Enteropathic Arthropathies
- Part 11. Systemic Lupus Erythematosus and Related Syndromes
- 80. Etiology and Pathogenesis of Systemic Lupus Erythematosus
- Introduction
- Historic View of Systemic Lupus Erythematosus Pathogenesis
- Genetic Contributions to Systemic Lupus Erythematosus Pathogenesis
- Female Predominance of Systemic Lupus Erythematosus
- Environmental Triggers of Systemic Lupus Erythematosus
- Innate Immune System Activation in Systemic Lupus Erythematosus
- Adaptive Immune System Alterations in Systemic Lupus Erythematosus
- Autoantibodies in Systemic Lupus Erythematosus
- Mechanisms of Target Organ Damage
- Conclusion
- 81. Clinical Features of Systemic Lupus Erythematosus
- Introduction
- Epidemiology
- Clinical Features
- Diagnosis
- Differential Diagnosis
- Neonatal Lupus
- 82. Treatment of Systemic Lupus Erythematosus
- Clinical Course and General Treatment Strategy
- Patient and Physician Preferences
- Drugs Used in the Treatment of Systemic Lupus Erythematosus
- Management of Specific Systemic Lupus Erythematosus Manifestations and Treatment Algorithms
- Special Issues: Treat-to-Target, Refractory Disease and Lupus in Pregnancy
- Comorbidities
- Evidence and Expert-Based Recommendations in Systemic Lupus Erythematosus
- Current Trends and Future Perspectives
- 83. Antiphospholipid Syndrome
- Introduction
- Epidemiology
- Etiology
- Pathogenesis
- Clinical Features
- Diagnosis
- Management
- Outcome
- Part 12. Systemic Sclerosis, Inflammatory Myopathies, and Overlap Syndromes
- 84. Etiology and Pathogenesis of Systemic Sclerosis
- Introduction
- Etiology
- Infectious Agents and Viruses
- Environmental Exposures, Dietary Factors, Drugs, and Radiation
- Microbiome Alterations in Systemic Sclerosis
- Microchimerism
- Pathology
- Organ-Specific Pathologic Findings
- Animal Models of Scleroderma
- Pathogenesis
- Inflammation and Immune Dysregulation in the Pathogenesis of Systemic Sclerosis
- Humoral Autoimmunity and B Cells
- Fibrosis
- Cellular Senescence and Fibrosis in Systemic Sclerosis
- Molecular Determinants of Fibrosis: Transforming Growth Factor-β
- Cytokines, Growth Factors, Chemokines, and Lipid Mediators
- Scleroderma Fibroblast
- Conclusion
- 85. Clinical Features and Treatment of Scleroderma
- Epidemiology
- Clinical Features
- General Principles of Disease Evaluation
- General Guidelines for Management
- Raynaud’s Phenomenon
- Skin Involvement
- Interstitial Lung Disease
- Pulmonary Hypertension
- Renal Involvement
- Gastrointestinal Involvement
- Primary Cardiac Involvement
- Musculoskeletal Involvement
- Associated Disorders
- Psychosocial Aspects
- Conclusion and Practical Recommendations
- 86. Inflammatory Diseases of Muscle and Other Myopathies
- Introduction
- Epidemiology
- Etiology of Myositis
- Pathogenesis
- Clinical Features
- Classification and Diagnostic Criteria
- Clinical Evaluation
- Management and Outcome
- 87. Overlap Syndromes
- Introduction
- Historical Background
- Immunogenetics of Overlap Syndromes
- Autoantibodies in Overlap Syndromes
- Mixed Connective Tissue Disease
- Patients Presenting With Undifferentiated Rheumatic Disease
- Overlap Syndromes With Dominant Features of Scleroderma
- Overlap Syndromes With Dominant Features of Myositis
- Sjögren’s Syndrome and Autoimmune Thyroid Disease
- Treatment of Overlap Connective Tisue Disease Syndromes
- Part 13. Vasculitis
- 88. Classification and Epidemiology of Systemic Vasculitis
- Introduction
- Classification of Vasculitis
- Epidemiology of Vasculitis
- 89. Giant Cell Arteritis, Polymyalgia Rheumatica, and Takayasu’s Arteritis
- Introduction
- Giant Cell Arteritis and Polymyalgia Rheumatica
- Takayasu’s Arteritis
- 90. Anti-neutrophil Cytoplasmic Antibody–Associated Vasculitis
- Introduction
- Classification Criteria and Nomenclature
- Epidemiology
- Genetics
- Clinical Manifestations
- Diagnostic Testing
- Treatment
- Outcomes
- Pathogenesis
- Conclusion
- 91. Polyarteritis Nodosa
- Definition and Classification
- Epidemiology
- Etiology and Pathogenesis
- Clinical Features and Diagnostic Tests
- Differential Diagnosis
- Treatment
- Outcome
- Cutaneous Polyarteritis Nodosa
- Monogenic Mimic of Polyarteritis Nodosa: Deficiency of Adenosine Deaminase 2
- 92. Immune Complex–Mediated Small Vessel Vasculitis
- Introduction
- Pathogenesis
- Cutaneous Manifestations
- Pathology
- Differential Diagnosis
- Clinical Syndromes
- 93. Primary Central Nervous System Vasculitis
- Introduction
- Epidemiology
- Genetics
- Clinical Features
- CNSV Subsets
- Diagnosis and Diagnostic Tests
- Differential Diagnosis
- Treatment
- Outcome
- Conclusion
- 94. Behçet’s Disease
- Introduction
- Epidemiology
- Pathogenesis
- Clinical Features
- Diagnosis
- Treatment
- Prognosis
- Part 14. Crystal-Induced and Inflammasome-Mediated Inflammation
- 95. Pathogenesis of Inflammasome-Mediated Diseases
- Introduction
- Inflammasome Biology
- Functional Inflammasomes
- Other Inflammasomes
- Inflammasomes in Autoimmunity
- Inflammasome-Targeted Therapies
- Conclusion
- 96. Etiology and Pathogenesis of Hyperuricemia and Gout
- Introduction
- Evolutionary Considerations
- Determinants of Urate Levels
- Asymptomatic Hyperuricemia and the Biological Effects of Soluble Urate
- Crystal Formation: The Transition From Hyperuricemia to Gout
- Acute Gout Flares: The Inflammatory Response to MSU Crystals
- Chronic Gouty Arthritis and Tophaceous Gout
- Gout and Comorbidities
- 97. Clinical Features and Treatment of Gout
- Classification Criteria
- Clinical Features of Gout
- Gout Management
- Comorbidity Assessment and Management in Patients With Gout
- Outcome
- Strategies to Improve Gout Care
- 98. Calcium Crystal Disease: Calcium Pyrophosphate Deposition Disease and Basic Calcium Phosphate-Associated Syndromes
- Introduction
- Calcium Pyrophosphate Deposition Disease
- Basic Calcium Phosphate–Associated Arthritis
- 99. Familial and Nonfamilial Autoinflammatory Syndromes
- Introduction
- Inflammasomopathies and IL-1-Driven Autoinflammatory Diseases
- Interferonopathies
- NF-κB-Related and/or Aberrant TNF Activity Autoinflammatory Syndromes
- Ubiquitination Defects
- Other Autoinflammatory Diseases
- Diagnostic Approach to Autoinflammatory Diseases
- Treatment of Autoinflammatory Diseases
- Conclusion
- Part 15. Cartilage, Bone, and Heritable Connective Tissue Disorders
- 100. Etiology and Pathogenesis of Osteoarthritis
- Introduction
- The Synovial Joint Is an Organ
- Endogenous Joint Tissue Repair Processes
- Osteoarthritis Risk Factors and Their Effects on Joint Physiology
- Pain Experiences and Nociceptive Signaling in OA
- Joint Tissue Damage
- Conclusion
- 101. Clinical Features of Osteoarthritis
- Introduction
- Epidemiology of Osteoarthritis
- Phenotypes in OA
- Clinical Features
- Diagnostic Tests
- Outcome
- Conclusion
- 102. Treatment of Osteoarthritis
- Introduction
- Therapeutic Pain Targets in Osteoarthritis
- Approach to Management of Osteoarthritis
- Experimental Osteoarthritis Therapies Under Development
- 103. Metabolic Bone Disease
- Introduction
- Osteoporosis
- Treatment
- Glucocorticoid-Induced Osteoporosis
- Osteomalacia
- Hypophosphatasia
- Paget’s Disease of Bone
- Osteoporosis Induced by Other Medications
- 104. Proliferative Bone Diseases
- Introduction
- Diffuse Idiopathic Skeletal Hyperostosis
- Hypertrophic Osteoarthropathy
- SAPHO Syndrome
- 105. Osteonecrosis
- Introduction
- Epidemiology
- Etiology
- Clinical Variants
- Staging Osteonecrosis
- Pathogenesis
- Genetic and Epigenetic Regulation in Osteonecrosis
- Diagnosis
- The Natural History of Osteonecrosis
- Treatment of Osteonecrosis
- Conclusion
- 106. Relapsing Polychondritis
- Introduction
- Epidemiology
- Pathology
- Pathogenesis
- Clinical Features
- Associated Disorders
- Differential Diagnosis
- Diagnostic Tests
- Treatment
- Outcome
- Conclusion
- 107. Heritable Diseases of Connective Tissues
- Introduction
- Skeletal Dysplasias: Overview
- Specific Heritable Disorders of Connective Tissue
- Conclusion
- Part 16. Rheumatic Diseases of Childhood
- 108. Etiology and Pathogenesis of Juvenile Idiopathic Arthritis
- Introduction
- Epidemiology
- Histopathology
- JIA Pathogenesis
- Subtype-Specific Pathogenesis
- Conclusion
- 109. Clinical Features and Treatment of Juvenile Idiopathic Arthritis
- Introduction
- Classification Criteria for Juvenile Idiopathic Arthritis and Differential Diagnosis
- Oligoarticular Juvenile Idiopathic Arthritis
- Rheumatoid Factor–Negative Polyarticular Juvenile Idiopathic Arthritis
- Rheumatoid Factor–Positive Polyarticular Juvenile Idiopathic Arthritis
- Juvenile Spondyloarthritis and Enthesitis-Related Arthritis
- Juvenile Psoriatic Arthritis
- Systemic Juvenile Idiopathic Arthritis
- Treatment—Medical Therapy
- Treatment of Juvenile Idiopathic Arthritis Subtypes
- Clinical Features and Management of Juvenile Idiopathic Arthritis–Associated Uveitis
- Imaging
- Outcomes
- Special Considerations in Children
- Conclusion
- 110. Childhood-Onset Systemic Lupus Erythematosus, Drug-Induced Lupus in Children, and Neonatal Lupus
- Childhood-Onset Systemic Lupus Erythematosus
- Drug-Induced Lupus
- Neonatal Lupus
- Conclusion
- 111. Juvenile Dermatomyositis, Scleroderma, and Vasculitis
- Juvenile Dermatomyositis
- Pediatric Scleroderma: Systemic and Localized Forms
- Pediatric Vasculitis
- Part 17. Infections and Rheumatic Disease
- 112. Bacterial Arthritis
- Epidemiology
- Nongonococcal Arthritis
- Prosthetic Joint Infections
- Conclusion
- 113. Lyme Disease
- Introduction
- Ecology and Epidemiology of Lyme Disease
- Ticks and Lyme Disease
- Pathogenesis
- Clinical Features of Lyme Disease
- Lyme Arthritis and Other Musculoskeletal Manifestations of Lyme Disease
- Diagnosis
- Treatment
- Special Considerations
- Outcomes
- Post-treatment Lyme Disease Syndrome
- Prevention
- Conclusion
- 114. Mycobacterial Infections of Bones and Joints
- Introduction
- Clinical Scenarios
- Diagnosis
- Treatment
- Osteoarticular Infections Caused by Nontuberculous Mycobacteria
- Emergence of Nontuberculous Mycobacterial Infections During the Treatment of Rheumatic Diseases
- 115. Fungal Infections of Bones and Joints
- Introduction
- Coccidioidomycosis
- Blastomycosis
- Cryptococcosis
- Candidiasis
- Sporotrichosis
- Aspergillosis
- Histoplasmosis
- Scedosporiosis
- Treatment of Fungal Infection
- Fungal Infection as a Consequence of Anti-rheumatic Therapy
- 116. Rheumatic Manifestations of Human Immunodeficiency Virus Infection
- Introduction
- HIV-Associated Bone and Joint Disease
- HIV-Associated Muscle Disease
- Diffuse Infiltrative Lymphocytosis Syndrome
- Vasculitis Associated With HIV Infection
- Thrombotic Thrombocytopenic Purpura
- Primary Pulmonary Hypertension
- HIV-Associated Musculoskeletal Infection
- Response of Other Rheumatic Diseases to HIV Infection
- HAART-Related Immune Reconstitution Syndrome
- Laboratory Abnormalities Associated With HIV Infection
- Conclusion
- 117. Viral Arthritis
- Introduction
- Examples of Arthritogenic Viruses
- Arthritogenic Viruses Hijack the Innate Interferon Type I Response to Favor Persistence
- Arthritogenic Viruses Engage Trojan Horse Scenario to Avoid Adaptive Immunity
- Other Mechanisms Favoring Viral Persistence Inside Synovial Tissues
- Mechanisms Involved in Chronic Arthralgias
- Mechanisms Involved in Chronic Inflammatory Viral Arthritis Resembling Rheumatoid Arthritis
- Treatment and Prevention
- Conclusion
- 118. Rheumatic Fever and Post-streptococcal Arthritis
- Introduction
- Rheumatic Fever and Rheumatic Heart Disease
- Post-streptococcal Arthritis
- Conclusion
- 119. COVID-19 and Rheumatic Disease
- Introduction
- Risk of SARS-CoV-2 Infection
- Impact of Immunosuppression on COVID-19 Outcomes
- Multisystem Inflammatory Syndrome in Children and Adults
- Autoantibodies and De Novo Autoimmune Disease in COVID-19
- Strategies to Mitigate Poor COVID-19 Outcomes in Immunosuppressed Patients With Rheumatic Disease
- Conclusion
- 120. Vaccination in Rheumatic Disease
- Introduction
- Influenza Vaccine
- Pneumococcal Vaccination
- Herpes Zoster Vaccination
- SARS-CoV-2 Vaccination
- Hepatitis B Vaccination
- Human Papilloma Virus Vaccination
- Tetanus Vaccination
- Yellow Fever Vaccination
- Conclusions
- Part 18. Arthritis Accompanying Systemic Disease
- 121. Amyloidosis
- Introduction
- Diagnosis of Amyloidosis
- AA Amyloidosis
- Epidemiology of AA Amyloidosis
- Genetics of AA Amyloidosis
- Clinical Features of AA Amyloidosis
- Other Important Types of Systemic Amyloidosis
- Diagnostic Tests for AA Amyloidosis
- Treatment of AA Amyloidosis
- Outcomes
- Conclusion
- 122. Sarcoidosis
- Introduction
- Classification Criteria
- Epidemiology
- Etiology
- Genetics
- Pathogenesis
- Clinical Features
- Diagnosis and Diagnostic Tests
- Treatment
- Outcome and Prognosis
- Conclusion
- 123. Hemochromatosis
- Introduction
- Iron Metabolism in Health and Disease
- Genetics
- Epidemiology
- Influence of Other Genes and Environment
- Pathogenesis
- Clinical Features
- Differential Diagnosis
- Diagnostic Tests
- Screening
- Treatment
- Outcomes
- Conclusion
- 124. Hemophilic Arthropathy
- Introduction
- Clinical Features
- Diagnosis
- Pathogenesis
- Treatment of Hemophilia
- Conclusion
- 125. Rheumatic Manifestations of Hemoglobinopathies
- Introduction
- Thalassemia
- Sickle Cell Anemia and Related Disorders
- Musculoskeletal Involvement: Sickle Cell Disease
- Musculoskeletal Involvement: Thalassemia
- Iron Metabolism
- Comorbid Rheumatic Disease
- Conclusion
- 126. IgG4-Related Disease
- Introduction
- Epidemiology
- Classification Criteria
- Pathology Features
- Serum IgG4 Concentrations
- Pathophysiology
- B Cell Lineage
- T Cells
- T Follicular Helper Cells
- CD4+ Cytotoxic T Lymphocytes
- Clinical Manifestations
- Proliferative Versus Fibrotic Subsets of Disease Manifestations
- Differential Diagnosis
- Treatment
- 127. Arthritis Accompanying Endocrine and Metabolic Disorders
- Introduction
- Adrenal Gland Disorders
- Acromegaly
- Hypothalamic–Gonadal Axis
- Diabetes Mellitus
- Bone Mineral Disease
- Thyroid Disease
- Hypothyroidism
- Parathyroid Disease
- Hyperparathyroidism
- Lipid Disorders
- 128. Rheumatic Paraneoplastic Syndromes and Malignancies With Rheumatic Manifestations
- Introduction
- Paraneoplastic Arthritis
- Palmar Fasciitis and Polyarthritis Syndrome
- Remitting Seronegative Symmetric Synovitis With Pitting Edema
- Pancreatic Panniculitis and Polyarthritis
- Erythromelalgia
- Paraneoplastic Vasculitis
- Hypertrophic (Pulmonary) Osteoarthropathy
- Eosinophilic Fasciitis
- Tumor-Induced Osteomalacia
- Cancer-Associated Myositis and Scleroderma
- Malignancies With Musculoskeletal Manifestations
- Cancer Treatments and Rheumatic Manifestations
- Conclusion
- 129. Tumors and Tumor-like Lesions of Joints and Related Structures
- Introduction
- Non-neoplastic Lesions
- Neoplasms
- Malignant Tumors of the Joint
- Primary Sarcomas of Joints
- Secondary Malignant Tumors of the Joint
- 130. Autoimmune Complications of Immune Checkpoint Inhibitors for Cancer
- Introduction
- Immune-Related Adverse Events
- Rheumatologic Immune-Related Adverse Events
- Treatment of Rheumatologic Immune-Related Adverse Events
- Pre-existing Autoimmune Disease and Immune Checkpoint Inhibitor Use
- Index
- Chapter Acknowledgments
- Chapter Acknowledgments
- No. of pages: 2496
- Language: English
- Edition: 12
- Published: July 24, 2024
- Imprint: Elsevier
- Hardback ISBN: 9780323935401
- eBook ISBN: 9780443350511
- eBook ISBN: 9780323935906
GF
Gary S. Firestein
Gary Firestein, MD, is a board-certified rheumatologist who diagnoses and treats patients with autoimmune conditions as well as diseases of the joints, muscles and bones. A professor at UC San Diego School of Medicine, Dr. Firestein is distinguished for his research and serves as director of the Altman Clinical and Translational Research Institute and the senior associate vice chancellor for health sciences. Dr. Firestein's research interest focuses on the pathogenesis and treatment of rheumatoid arthritis.
Dr. Firestein is the recipient of many awards and honors, including the Arthritis Foundation's Jane Wyman Humanitarian Award in 2010 for his contributions to rheumatology; the Arthritis Foundation Lee C. Howley Sr. Prize for Arthritis Research; and the American College of Rheumatology Distinguished Investigator Award. He has been elected to the American Society for Clinical Investigation and the Association of American Physicians. He has served as an editor for the Textbook of Rheumatology for since the 7th edition (2004).
Affiliations and expertise
Distinguished Professor of Medicine, Senior Associate Vice Chancellor for Health Sciences, Director, Altman Clinical & Translational Research InstituteIM
Iain B McInnes
Iain McInnes is Director of the Institute of Infection, Immunity and Inflammation at the University of Glasgow, UK. He has extensive experience in leading multicenter programs nationally and internationally. He is Director of the Scottish MRC Clinical Pharmacology and Pathology Clinical PhD Training Program, Chief Investigator for the Scottish Early RA Cohort (SERA) and the related SMS-IC biomarker discovery program (PROMISERA), and chief investigator of numerous global phase II and III clinical trials of novel immune therapies. He has served as member or chair of numerous national grant-funding panels and as chair of several European League Against Rheumatism (EULAR) scientific committees – he is now Treasurer and President Elect of EULAR serving on its Steering Committee. He is formerly Chairman of the Foundation for European Rheumatology Research (Foreum) Scientific Committee and leads the EULAR-supported European Roadmap Program that is defining the research agenda for rheumatology for the next decade.
Affiliations and expertise
Muirhead Professor of Medicine, Arthritis Research UK Professor of Rheumatology, Director of Institute of Infection,Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland, United KingdomGK
Gary Koretzky
Gary Koretzky, MD, PhD is Professor of Medicine at Weill Cornell Graduate School. Dr. Koretzky’s research aims to better understand the signal transduction events that occur following engagement of the T cell antigen receptor. He has been continuously funded by the National Institutes of Health since establishing his independent research group, as the laboratory has expanded its interests to study more globally the molecular events important for immune cell development, differentiation and function. Dr. Koretzky has published more than 200 research articles. He is a past President of the American Society of Clinical Investigation (2000) and Councilor of the Association of American Physicians (2008-2012), is a Fellow of the American Association for the Advancement of Science (2004), a member of the Institute of Medicine of the National Academies (2008), a Fellow of the American Academy of Arts & Sciences (2012) and serves as the Editor-in-Chief of Immunological Reviews (2002-present).
Affiliations and expertise
Vice Dean at Weill Cornell Medical College, Frank H.T. Rhodes Distinguished Professor of Cardiovascular Biology and Genetics.TM
Ted Mikuls
Dr. Mikuls is a rheumatologist and epidemiologist with research interests focused on the epidemiology, pathogenesis, and outcomes of rheumatoid arthritis (RA) and gout. He is actively engaged in clinical/translational research activities and has received research funding from the NIH, U.S. Department of Defense, Veterans Affairs, the Rheumatology Research Foundation, and industry. He has extensive experience conducting multi-center / multidisciplinary trials, serving as the Principal Investigator (PI) for the multicenter Veterans Affairs Rheumatoid Arthritis (VARA) registry since its inception in 2003. He has served on multiple national study sections including those convened by the NIH, VA, and the Rheumatology Research Foundation. He previously chaired the American College of Rheumatology (ACR) Subcommittee for Practice Guidelines, served on the US FDA’s Arthritis Advisory Committee, and was the Lead Editor for the textbook A Color Handbook – Rheumatology.
Affiliations and expertise
Stokes Shackleford Professor and Vice-Chair for Research, Internal Medicine, Division of Rheumatology, University of Nebraska Medical CenterTN
Tuhina Neogi
Tuhina Neogi is a rheumatologist and epidemiologist whose research has focused primarily on risk factors for knee osteoarthritis and gout, pain mechanisms in knee osteoarthritis, as well as methodologic issues of relevance for rheumatic diseases. Dr. Neogi has had continuous peer-reviewed foundation and NIH funding since 2003 and has over 250 peer-reviewed publications to date. She is a past chair of the FDA Arthritis Advisory Committee, serve(d) on the boards of two international societies: Osteoarthritis Research Society International (OARSI) and Gout, Hyperuricemia, and Crystal-Associated Diseases Network (G-CAN), and on committees for the American College of Rheumatology (ACR) and International Association for the Study Pain (IASP), among others. Her work has been recognized with the prestigious 2014 ACR Henry Kunkel Young Investigator Award for outstanding and promising independent contributions to rheumatology research and she has also engaged in developing new classification criteria for a number of rheumatic diseases.
Affiliations and expertise
Section Chief of Rheumatology, Rheumatology, Professor, Rheumatology, Boston University School of MedicineJO
James R. O'Dell
James R. O’Dell, MD is the Stokes Shackleford Professor of Internal Medicine, Vice-Chairman of Internal Medicine and Chief of the Division of Rheumatology at the University of Nebraska Medical Center (UNMC) in Omaha. Dr. O’Dell founded and has directed the Rheumatoid Arthritis Investigational Network (RAIN) for the last 25 years. Dr. O’Dell is the PI of the large multinational RA research study based at the VA through their cooperative studies program. Dr. O’Dell has published extensively, mostly in the area of rheumatoid arthritis. He has presented frequently at national and international meetings and has more than 100 published articles in top-level rheumatology journals. He has served on numerous American College of Rheumatology (ACR) committees over the last 20 years, including time on both the ACR and REF BOD, as well as a two-year term as President of the Research and Education Foundation of the ACR and was President of the College (2011-2012). Additionally, he is Editor-in-Chief of Up To Date for Rheumatology.
Affiliations and expertise
Bruce Professor and Vice Chairman of Internal Medicine, University of Nebraska Medical Center, Chief of Rheumatology, Department of Medicine, Omaha Veterans Affairs, Omaha, Nebraska